EATONTOWN, N.J., April 10 /PRNewswire/ -- Roberts Pharmaceutical
Corporation (Nasdaq: RPCX) announced today that David S. Tierney, M.D.,
formerly of Elan Pharmaceutical Research Corporation, has joined Roberts as
Senior Vice President, Medical and Regulatory Affairs.
    In this newly created position, Dr. Tierney will assume overall
responsibility for the drug development program at Roberts which, in recent
months, has been significantly expanded with the addition of compounds
licensed from Lilly and Pfizer that address potentially large markets.
Reporting to Dr. Tierney will be the Medical Affairs, Worldwide Regulatory
Affairs, and Chemical Process Development Departments at Roberts.
    Before joining Roberts, Dr. Tierney held senior positions with Elan
Pharmaceutical Research where his responsibilities included global clinical
development of new compounds in several different therapeutic categories.
Most recently he served Elan Pharmaceutical Research as Head of Worldwide
Clinical Research and prior to that as Director of Medical Affairs. Dr.
Tierney is a graduate of the Medical School of the Royal College of Surgeons,
Dublin, Ireland.
    Commenting on the announcement, Robert W. Loy, Executive Vice President,
Operations and New Business Development for Roberts said, "David possesses an
abundance of experience in pharmaceutical product development.  His background
and experiences should strongly augment our very fine staff of professionals
and this Company's commitment to bringing new products through development
into the market."
    Roberts Pharmaceutical Corporation, with operating subsidiaries in the
United States, Canada, and the United Kingdom, focuses on new health care
solutions through the acquisition and development of specialty
pharmaceuticals.  The Company's first proprietary product, PROAMATINE (R), was
recently launched in the U.S. as the first drug for treating orthostatic
hypotension.  AGRYLIN (TM), Roberts' second pipeline product, has since been
launched as the first FDA approved drug for treating essential
thrombocythemia.
    Recent press releases and a letter from the Chairman of the Board of
Roberts Pharmaceutical Corporation are available through PR Newswire's Company
News On-Call fax service at 1-800-758-5804, extension 760975 and on the
internet at http://www.prnewswire.com
    This release may contain forward-looking statements which reflect
management's current views of future events and operations.  These
forward-looking statements are based on assumptions and external factors,
including assumptions relating to regulatory action and competing products.
Any changes in such assumptions or external factors could produce
significantly different results.

Link to this page: